The global Acute Myeloid Leukemia (AML) therapeutics market is poised for substantial growth, with projections indicating an increase from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, according to a new report by Fact.MR. This represents a compound annual growth rate (CAGR) of 9.2% over the forecast period, creating an absolute dollar opportunity of approximately USD 5.9 billion. The expansion is largely attributed to the shift toward genomics-driven treatment strategies and the adoption of targeted therapies that are transforming AML management.
According to the report, targeted therapies are expected to account for 36% of market share in 2026, making them the leading drug class. These mutation-directed treatments, which target genetic abnormalities such as FLT3 and NPM1, are enabling more personalized care and improving patient outcomes. The newly diagnosed AML segment is projected to hold 48% of the market share, as initial treatment regimens generate the highest therapy volumes. Hospitals remain the primary end-users, comprising 55% of market demand, due to the intensive nature of AML treatment, including chemotherapy administration and continuous monitoring.
The report highlights that precision oncology is revolutionizing AML treatment, with clinicians increasingly relying on molecular testing and genomic profiling to guide therapy decisions. This approach helps identify the most effective treatments for specific patient populations while reducing unnecessary toxicity. The growing focus on relapsed and refractory AML is also creating new opportunities, as novel oral targeted therapies, menin inhibitors, and mutation-specific treatments expand options for patients with limited alternatives.
Regionally, South Asia and East Asia are emerging as high-growth areas, driven by expanding cancer care infrastructure and increased access to molecular diagnostics. India is projected to grow at a CAGR of 11.8%, followed by China at 10.9%, and the United States at 8.7%. North America continues to lead market revenues due to strong specialty pharmacy networks and high healthcare spending.
Key players in the competitive landscape include AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc. These companies are investing heavily in precision medicine, molecular diagnostics partnerships, and clinical trials to strengthen their positions. The report also notes that hospital pharmacies dominate sales channels with a 49% share, reflecting the complexity of AML therapies and the need for specialized handling.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR, the future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability. The full report is available at Fact.MR.
While challenges such as treatment costs, toxicity management, and reimbursement constraints remain, the long-term outlook for the AML therapeutics market is highly positive. Continued advances in precision oncology, lower-intensity regimens, and next-generation immuno-oncology approaches are expected to further expand treatment opportunities and improve patient outcomes globally.
